BIOCRYST PHARMACEUTICALS, INC. Available-for-sale Securities, Gross Unrealized Loss
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Available-for-sale Securities, Gross Unrealized Loss of $27.00 thousand for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2015-05-08
- BIOCRYST PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2015-03-31 was $27.00K.
- BIOCRYST PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for fiscal 2013 was $1.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|
| 2015-03-31 | $27.00K 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $133.00K 10-Q · filed 2015-05-08 | |
| 2013-12-31 | $1.00K 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |